Tumor markers as targets for selective diagnostic and therapeutic procedures. 1996

M Roselli, and F Guadagni, and O Buonomo, and A Belardi, and P Ferroni, and A Diodati, and D Anselmi, and C Cipriani, and C U Casciani, and J Greiner, and J Schlom
Department of Surgery, University of Rome Tor Vergata, Italy.

Monoclonal antibodies (MAbs) that are reactive with tumor associated antigens (TAAs) have led to many of the recent advances made in tumor immunology. At the present time, many of these MAbs have already been used in various aspects of patient management and in better understanding the biology of carcinoma cell populations. Because of their diversity, specificity and biological activity, these MAbs are potentially ideal agents for a variety of applications in malignant disorders such as, clinical diagnosis using serum assays, immunocytopathological analyses of effusions or fine-needle aspiration specimens, immunoscintigraphy, radioimmunoguided surgery and, with additional development, site directed immunotherapy. Nevertheless, their clinical application shows advantages and limitations. Optimization of their clinical use is actually under evaluation in several Institutions, including our Department. Many innovations have been developed over the last decade which may enhance their clinical efficacy. In this view, an optimal tumor targeting for diagnostic or therapeutic applications may require a better choice of radiotracer, generation of new molecules and the characterization of TAAs at the target level.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D016719 Radioimmunodetection Use of radiolabeled antibodies for diagnostic imaging of neoplasms. Antitumor antibodies are labeled with diverse radionuclides including iodine-131, iodine-123, indium-111, or technetium-99m and injected into the patient. Images are obtained by a scintillation camera. Immunoscintigraphy, Radiolabeled,Radioimmunoimaging,Radioimmunoscintigraphy,Immunoscintigraphy, Radiolabelled,Radiolabeled Immunoscintigraphy,Radiolabelled Immunoscintigraphy,Immunoscintigraphies, Radiolabeled,Immunoscintigraphies, Radiolabelled,Radioimmunodetections,Radioimmunoimagings,Radioimmunoscintigraphies,Radiolabeled Immunoscintigraphies,Radiolabelled Immunoscintigraphies

Related Publications

M Roselli, and F Guadagni, and O Buonomo, and A Belardi, and P Ferroni, and A Diodati, and D Anselmi, and C Cipriani, and C U Casciani, and J Greiner, and J Schlom
November 2017, Neural regeneration research,
M Roselli, and F Guadagni, and O Buonomo, and A Belardi, and P Ferroni, and A Diodati, and D Anselmi, and C Cipriani, and C U Casciani, and J Greiner, and J Schlom
September 2023, Pathology, research and practice,
M Roselli, and F Guadagni, and O Buonomo, and A Belardi, and P Ferroni, and A Diodati, and D Anselmi, and C Cipriani, and C U Casciani, and J Greiner, and J Schlom
January 1992, Important advances in oncology,
M Roselli, and F Guadagni, and O Buonomo, and A Belardi, and P Ferroni, and A Diodati, and D Anselmi, and C Cipriani, and C U Casciani, and J Greiner, and J Schlom
February 2013, Trends in molecular medicine,
M Roselli, and F Guadagni, and O Buonomo, and A Belardi, and P Ferroni, and A Diodati, and D Anselmi, and C Cipriani, and C U Casciani, and J Greiner, and J Schlom
April 2022, Bulletin of experimental biology and medicine,
M Roselli, and F Guadagni, and O Buonomo, and A Belardi, and P Ferroni, and A Diodati, and D Anselmi, and C Cipriani, and C U Casciani, and J Greiner, and J Schlom
March 2022, Biomedicines,
M Roselli, and F Guadagni, and O Buonomo, and A Belardi, and P Ferroni, and A Diodati, and D Anselmi, and C Cipriani, and C U Casciani, and J Greiner, and J Schlom
December 2019, International journal of medical microbiology : IJMM,
M Roselli, and F Guadagni, and O Buonomo, and A Belardi, and P Ferroni, and A Diodati, and D Anselmi, and C Cipriani, and C U Casciani, and J Greiner, and J Schlom
May 2024, Journal of translational medicine,
M Roselli, and F Guadagni, and O Buonomo, and A Belardi, and P Ferroni, and A Diodati, and D Anselmi, and C Cipriani, and C U Casciani, and J Greiner, and J Schlom
January 2022, Frontiers in pharmacology,
M Roselli, and F Guadagni, and O Buonomo, and A Belardi, and P Ferroni, and A Diodati, and D Anselmi, and C Cipriani, and C U Casciani, and J Greiner, and J Schlom
August 2013, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Copied contents to your clipboard!